Screener
Mirum Pharmaceuticals, Inc. MIRM Convertible Notes Payable
Convertible Notes Payable at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ConvertibleNotesPayable.
The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001759425-26-000045
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| 0.00% senior subordinated convertible notes due in June 2032 | 690,000 | — |
| Unamortized debt discount and issuance costs | (17,577) | — |
| 2032 Notes, net | 672,423 | — |
| Total convertible notes payable, net | $750,079 | $309,797 |
| Fair value of fixed rate convertible notes (1): | ||
| 2029 Notes | $294,309 | $818,485 |
| 2032 Notes | 746,815 | — |
| Total fair value of fixed rate convertible notes | $1,041,124 | $818,485 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Mirum Pharmaceuticals, Inc.'s convertible notes payable?
- Mirum Pharmaceuticals, Inc. (MIRM) reported convertible notes payable of $750.08M in Q2 2026.
- What does convertible notes payable mean?
- Convertible Notes Payable
Ask your AI about Mirum Pharmaceuticals, Inc.'s convertible notes payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude